Rivaroxaban Data at the 2011 AHA Scientific Sessions

November 12 - 16, 2011
Orlando, Florida, USA

Results from the Phase III ATLAS ACS 2 TIMI 51 clinical trial of rivaroxaban (Xarelto®) have been presented in the Late Breaking Clinical Trials Session of the American Heart Association's Scientific Sessions 2011 by C. Michael Gibson, M.S., M.D., TIMI Study Group, Boston, MA, on Sunday, November 13, from 5:13 PM - 5:23 PM (ET).

On this occasion we held a conference call for investors and analysts on November 14, 2011 at approx. 12:30 p.m. CET (11:30 a.m. GMT).

Monday, November 14:
Investor Conference Call on Rivaroxaban

Dr. Kemal Malik, Head of Global Development at Bayer HealthCare Pharmaceuticals 
Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular and Coagulation, Global Clinical Development
Dr. Alexander Rosar, Head of Investor Relations

Audio recording (MP3 format)